Outcomes of acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy is challenging. Hypomethylating agents (HMAs) can be effective in these patients but responses are usually short-lived. The majority of patients will either have stable disease or progress through therapy. We hereby describe the outcome of these patients at our institution after they fail HMAs. The data on 56 AML patients at Mayo Clinic, Rochester were reviewed. Patients were considered for our study if they received HMA as frontline therapy for their AML. Out of 56 patients, 15 (27%) patients received azacitidine (AZA) and 41 (73%) received decitabine. Complete remission was found in 10 (18%), with overall response of 28% and median response duration of 10 months. Thirteen (81%) out of 16 responders relapsed. Therefore 53 patients were included in the primary or secondary failure analysis with a median overall survival (OS) of 2 months after the date of failure. Out of 53 patients, 12 (23%) received subsequent treatments. None of the 12 patients who got first salvage therapy achieved remission. Five out of the 12 patients received second salvage therapy, 2 (40%) of which achieved CR. Median OS for patients who received subsequent salvage therapies was better than those who did not receive any subsequent therapy after failing HMA (9.5 vs. 2 months, P 5 .0009). Outcome for patients who have primary or secondary failure is very poor. Our study provides important historical data for future novel therapies, which are sorely needed for these patients.
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| I N T R O D U C T I O N
Acute myeloid leukemia (AML) is the most frequent form of acute leukemia in adults. Patients newly diagnosed with AML have a median age of 65 years, making it a disease of later adulthood. [1] [2] [3] [4] Elderly patients have higher rates of multidrug resistance and a higher prevalence of secondary AML (sAML) arising from myelodysplastic syndromes (MDS). Acquired chromosomal abnormalities, which are more frequent in secondary 5 and older AML patients, 6 are the most important predictor of short term and long term outcome. 7, 8 All of the aforementioned contribute to the poorer outcome of the elderly AML population. 1 Elderly patients with AML are frequently found to be "unfit" for intensive chemotherapy due to poor performance status and multiple comorbidities leading to poor tolerance to intensive treatment modalities. 9 In addition, intensive chemotherapy (IC) in elderly AML is associated with high likelihood of death within 30 days of initiating therapy. 10 Intensive chemotherapy has a lower complete remission (CR) rate when used for elderly as compared with younger patients with AML. 11 When elderly AML patients have favorable cytogenetics, IC can induce complete remission as often as 80%.
But despite these high CR rates, OS remains poor. 10, [12] [13] [14] [15] Hypomethylating agents (HMA) including azacitidine and decitabine, are approved to treat MDS 16, 17 and have recently shown clinical efficacy as frontline agents for the management of AML. 18 Despite the limited treatment options available to such patients, no standard salvage therapy is recommended for elderly AML patients after they fail HMAs because no data is available. We therefore, reviewed our experience with outcomes of elderly patients with AML after failure of HMA therapy.
| M E T H O D S
This is a retrospective single institution chart review study of patients with elderly AML (age 59), whether primary or secondary, who 
| Statistical analysis
Prognostic factors were analyzed by univariate analyses. Survival estimates were calculated using Kaplan-Meier curves and univariate and multivariate analyses was based on log-rank testing using JMP software version 10.
| R E S U L T S 3.1 | Characteristics at diagnosis
Fifty-six AML patients treated with HMA as frontline therapy were identified out of the initial 369 elderly AML patients seen at our institution (15%). The median age of these patients was 76 years (59-91), and 68% of them were males. Cases were classified as AML with myelodysplasia related changes in 25%, and therapy related MPN in 2%, and not otherwise specific in 73%. Out of 56 cases, 23% were secondary to MDS, 2% ET, 5% PV, 5% MF, 4% from CMML; while 61% were de novo AML. Per cytogenetics data, 2%
were considered favorable risk, 62% intermediate, and 36% poor (34% had a complex karyotype) ( Table 1) . Median overall survival (OS) from time of AML diagnosis to the date of last follow up was 9.5 months (Figure 1 ). 
| DISCUSSION
To the best of our knowledge, the current study is the first to present the outcome of a series of patients with AML who were unfit for IC and were treated with HMAs and whose disease failed to respond to an HMA or progressed after an initial clinical response. The median OS of 9.5 months confirmed their general poor outcome and the urgent need for improved salvage therapies.
Elderly AML has a poor prognosis. 9, 10 Intensive chemotherapy (IC)
is still the conventional treatment method for AML if fit for aggressive in those who responded. 26 These findings were comparable to our study where the overall response to HMAs was 28% with CR rates of 18%, CRi of 5%, and PR of 5% and relapse rate among responders was 81%.
| Azacitidine vs. decitabine
Three quarter of our patients received AZA. When compared to DAC, the median number of cycles of AZA received was higher (8 vs. 4) and the OS was 9.5 months for the entire cohort.
Lubbert et al. found CR rates to be 26% in a phase 2 trial of frontline DAC in elderly AML unfit for IC. 28 This was consistent with our study where we found total response rate to be 29% with DAC therapy with a CR rate of 17%, CRi of 7%, and PR of 5%. Azacytidine was shown to improve symptoms and slightly prolong overall survival when compared to conventional care regimens. 21 In a study where AZA was given to untreated elderly AML patients, the overall response rate was 33% and mOS was 9.4 months. 23 This was very comparable to our results where we found total response rates to AZA to be 27% (CR rate 20%). In our study, AZA had longer mOS than DAC (19 vs. 8 months) ( Figure S4 ). None of the previously mentioned studies compared AZA to DAC directly. Response rates and mOS found were comparable to our results and AZA does seem to have favorable mOS (5.5 vs. 9.4) despite similar response rates (26% for DAC vs. 33%). In our study, more patients received DAC compared to AZA, but the median number of AZA cycles was more and the duration of therapy was longer. Our findings further emphasize the efficacy of HMA as alternatives to BSC for patients who do not meet the criteria for IC.
For all patients, performance status and karyotype remain the strongest prognostic factors. [29] [30] [31] Most of our patients had higher risk cytogenetics (two-third intermediate risk and one-third poor risk including complex cytogenetics).
| Failure to HMA
Despite HMA being reasonable alternatives, response rates that HMA can achieve in this population are considered low and the OS is much less than desirable. This patient population is in dire need of more treatment options. In this study, we attempted to document the clinical outcome using different available therapies and the response rates associated with them to guide future prospective studies.
First of all, OS was very comparable between relapsed and refractory groups (4 vs. 2 months) (Supporting Information, item 2) indicating that both groups need novel treatments. Second, only 23% received subsequent line therapies, indicating the poor performance of this group and the lack of standard therapies. Some hematologists offer a switch option by giving another HMA (eg, offering DAC if patient fails AZA and vice versa). In our study, 1 quarter of these patients (3) were switched to a different HMA but none had a response. Duong at al found lack of response in MDS/MPN and elderly AML to DAC after failing AZA. 32 Our study confirmed this since no benefit was found after the switch and no patient achieved any response.
The outcome after any type of treatment appeared better than supportive care as confirmed in our study (9.5 mOS of subsequently treated patients vs. 2 months in the non-treated group) although response rates were not any better (none of the patients who received first line salvage therapy achieved remission). This might be due to the greater level of care provided to the treated patients in addition to the recent improvements in supportive care and potentially to selection bias of patients who were fit to receive further therapies.
Low dose cytarabine (LDAC) is still a standard therapy for elderly unfit AML. A recent study has shown it to be superior to best supportive care (BSC) when offered as frontline for AML patients unfit for IC.
In this study, CR rates associated with LDAC were lower than the rates with IC or HMA (7% vs. 56% and 21%, respectively). The OS was also lower but it was not statistically significant. 33 Low dose cytarabine has never been studied as a subsequent line therapy after failure to HMAs in elderly AML. In our study, 2 patients (17%) received LDAC and neither of them achieved CR. Overall survival was comparable to the rest of the subsequent line treatments. Low dose cytarabine was found to be less effective with poor cytogenetics. 33 Patients in our study who received LDAC had intermediate risk cytogenetics.
Other novel agents in combination with LDAC and/or HMAs are currently under development and in phase 2 and 3 trials, although none has reported improvement in OS. 34 Two of our patients received subsequent line treatments that were part of clinical trials. No difference in response or OS was found between patients who were included in clinical trials and the rest of the patients who got other therapies as a subsequent line treatment.
Our study found all traditional salvage therapies and clinical trials that our patients underwent to be ineffective. None of the ongoing clinical trials show any promise yet. As a conclusion, we could not recommend 1 therapy over the other but our study emphasizes on the importance of new innovative therapies and trials.
Weaknesses of our study include the small number of patients and lack of long term follow up in all cases. In addition, our study suffers from the usual shortcomings of a retrospective study including documentation of responses and lack of rigorous follow up and repeat bone marrow biopsies. In our study we included only biopsy proven and centrally reviewed AML patients over an extended time frame seen at a single institution. Moreover, our study is the first to provide some insight into the different subsequent lines of therapies to elderly AML patients who fail frontline HMAs. In addition to the HMA response analysis, we also report the mOS analysis for patients who failed
HMAs which was grouped by type of response (refractory/relapse), whether patients received subsequent line therapy or not, and the specific HMA used (AZA vs. DAC). Larger studies from multiple centers will be required to validate the findings of our study. Dedicated studies for each type of treatment will be necessary to refine the response rates and prognostic factors associated with each group of patients.
The results of the current study define the poor outcome in elderly patients with AML after HMA failure (median survival 2 months). The treatment of these patients remains an unmet medical need. Investigational agents need to be tested in this setting. We believe the results presented herein should help to provide the historical data for future clinical trials in this population.
| C O NC LU S I O N S
Elderly patients diagnosed with AML who are unfit for intensive chemotherapy have a poor prognosis. HMA can get some patients into remission but most patients will ultimately fail. Outcome for patients who have primary or secondary (relapse) failure is very poor with a median OS of 2 months. Switch of HMA did not result in any response.
Response to salvage therapy continues to be low but offering salvage therapies may improve OS. Our study provides historical data for future novel therapies, which are needed for these patients.
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